Moderna Stock Five Year Return
MRNA Stock | USD 106.82 3.77 3.41% |
Moderna fundamentals help investors to digest information that contributes to Moderna's financial success or failures. It also enables traders to predict the movement of Moderna Stock. The fundamental analysis module provides a way to measure Moderna's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moderna stock.
Moderna | Five Year Return |
Moderna Five Year Return Analysis
Moderna's Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 18M | 200M | 405M | 425.3M | Net Interest Income | 18M | 200M | 363M | 381.2M |
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Moderna Five Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Moderna is extremely important. It helps to project a fair market value of Moderna Stock properly, considering its historical fundamentals such as Five Year Return. Since Moderna's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moderna's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moderna's interrelated accounts and indicators.
Click cells to compare fundamentals
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
Competition |
Moderna Return On Capital Employed
Return On Capital Employed |
|
According to the company disclosure, Moderna has a Five Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Moderna Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moderna's direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moderna could also be used in its relative valuation, which is a method of valuing Moderna by comparing valuation metrics of similar companies.Moderna is currently under evaluation in five year return category among related companies.
Moderna Fundamentals
Return On Equity | -0.29 | ||||
Return On Asset | -0.12 | ||||
Profit Margin | (0.69) % | ||||
Operating Margin | 0 % | ||||
Current Valuation | 34.99 B | ||||
Shares Outstanding | 382.88 M | ||||
Shares Owned By Insiders | 9.63 % | ||||
Shares Owned By Institutions | 71.81 % | ||||
Number Of Shares Shorted | 22.23 M | ||||
Price To Earning | 6.37 X | ||||
Price To Book | 3.06 X | ||||
Price To Sales | 6.18 X | ||||
Revenue | 6.75 B | ||||
Gross Profit | 10.55 B | ||||
EBITDA | (3.21 B) | ||||
Net Income | (4.71 B) | ||||
Cash And Equivalents | 8.35 B | ||||
Cash Per Share | 21.73 X | ||||
Total Debt | 1.24 B | ||||
Debt To Equity | 0.07 % | ||||
Current Ratio | 2.10 X | ||||
Book Value Per Share | 36.27 X | ||||
Cash Flow From Operations | (3.12 B) | ||||
Short Ratio | 5.38 X | ||||
Earnings Per Share | (12.33) X | ||||
Target Price | 131.57 | ||||
Number Of Employees | 5.6 K | ||||
Beta | 1.6 | ||||
Market Capitalization | 42.34 B | ||||
Total Asset | 18.43 B | ||||
Retained Earnings | 13.61 B | ||||
Working Capital | 7.31 B | ||||
Current Asset | 850 K | ||||
Current Liabilities | 2.44 M | ||||
Z Score | 21.74 | ||||
Net Asset | 18.43 B |
About Moderna Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moderna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moderna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moderna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3700 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Moderna Piotroski F Score and Moderna Altman Z Score analysis. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (12.33) | Revenue Per Share 17.927 | Quarterly Revenue Growth (0.45) | Return On Assets (0.12) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.